At a time when healthcare systems worldwide are under increasing pressure to improve patient safety, reduce hospital-acquired infections, and deliver more precise cancer treatments, CS Diagnostics Corp. (OTCQB: CSDX) is…
American Lithium Minerals (OTC: AMLM) is quietly assembling what many investors are actively searching for in today’s market: a diversified, multi-jurisdiction portfolio of critical minerals and precious metals, anchored in…
As gold prices remain resilient amid geopolitical uncertainty, central-bank accumulation, and persistent inflationary pressure, investors are increasingly rotating back into gold equities—particularly micro-cap names with identifiable catalysts. One company now…
ADM Endeavors (OTCQB: ADMQ) is quietly transforming itself from a steady promotional products business into a scalable, vertically integrated manufacturing and government-facing platform—a shift that is beginning to attract attention…
Power Metallic Mines Inc., formerly Power Nickel Inc., is entering 2026 with one of the most compelling polymetallic and critical-minerals narratives in the junior mining sector. The company’s evolution reflects…
American Lithium Minerals (OTCID: AMLM) continues to reposition itself as a diversified, U.S.-anchored critical minerals company as it advances a series of mineral acquisitions spanning North America, South America, and…
In a market increasingly driven by speed, convenience, and consumer compliance, one delivery technology is quietly re-emerging as a potential breakout theme: oral thin film delivery. At the center of…
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) is drawing increased investor and healthcare-industry attention following a featured interview with CEO Dimitar Savov on The Street Reports Podcast. During the discussion, Savov outlined…
ENDRA Life Sciences (NASDAQ: NDRA), a pioneer in next-generation medical imaging for the early detection and monitoring of liver disease, is redefining strategic finance for public companies through an innovative…
Aprea Therapeutics (Nasdaq: APRE), a clinical-stage oncology company developing targeted cancer therapies, reported strong third quarter results and highlighted progress in two key drug programs aimed at treating solid tumors…
